In case of treatment studies, 2 biomarkers (FOXA1 and JUND) out of 16, do not have prognostic capability of differentiating between high-expression and low-expression groups of cancer patients, meaning hazard ratio is close to 1 (HR ≈1); 3 biomarkers (CEBPB, MYC and UBC) show that low-expression groups have higher chance of survival (HR >1); and the remaining 11 biomakers show that high-expression groups have higher chance of survival (HR <1). Here, FOXA1 is linked to cancer.